ExpreS2ion Biotechnologies: Expanding ES2B-C001 study to include combination testing
ExpreS2ion has today announced that it has submitted a study protocol amendment to the Austrian regulatory authorities for its Phase 1 ES2B-C001 breast cancer study. The amendment aims to enable evaluation of its breast cancer vaccine candidate, ES2B-C001, in combination with antibody-drug conjugates (ADCs), and to expand the number of study sites.
In addition to increasing the number of clinical trial sites in Austria—making it more likely that the study can be completed within the expected timeline—the inclusion of ES2B-C001 in combination treatments is also expected to accelerate patient recruitment. This is because combination therapy better aligns with current treatment standards, thereby increasing the number of eligible patients.
The company also states that these changes to the protocol are not expected to affect the overall timeline, as the original trial continues under the current protocol. An update on timelines will be provided when the first patient has been dosed.
Beyond supporting the study’s timely execution, testing ES2B-C001 in combination with other treatments could also generate additional data that may strengthen the commercial potential of the vaccine, as it has future potential to be used as an add-on to currently recommended treatments.
ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. At 10:30 CET on the same day, we are hosting an event with management. In addition to the quarterly results, the discussion could focus on today’s announcement and the potential of expanding the study, as well as the prospects of the recently announced partnership with WuXi Biologics regarding the ExpreS2™ technology platform.
Sign up for the event here: https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q1-2025
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement.— Michael Friis, 13:03, 13-05-2025
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Lue lisää yhtiösivulla